Incretin Atlas › Trials › Ribupatide phase 2 (obesity + PMOS)
Ribupatide phase 2 (obesity + PMOS)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Phase
- 2
- Participants
- 158
- Duration
- 32 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ribupatide 4 mg | obesity china | 32 | 158 | — | −20.2 % vs −2.6 % Δ −17.6 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | verified |
| ribupatide 2 mg | obesity china | 32 | 158 | — | −15.1 % vs −2.6 % Δ −12.5 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- ribupatide 4 mg: Treatment-policy estimand; duration to confirm from the abstract; duration 32 weeks per the abstract (both models agree) Per-arm N for the zero counts inferred from the reported percentages (≈39–40).
- ribupatide 2 mg: duration 32 weeks per the abstract (both models agree) Per-arm N for the zero counts inferred from the reported percentages (≈39–40).
Verbatim quotes from the source (6)
- ribupatide 4 mg · weight_tp · Results
the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
- ribupatide 4 mg · ae_dc · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 4 mg · sae · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 2 mg · weight_tp · Results
the least-squares (LS) mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1 mg, 2 mg and 4 mg, respectively, versus -2.6% with placebo
- ribupatide 2 mg · ae_dc · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- ribupatide 2 mg · sae · Results
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
Primary sources
- Hongwei Jiang et al. Efficacy and safety of ribupatide (HRS9531) in participants with obesity and polyendocrine metabolic ovarian syndrome (PMOS): a multicentre, randomised, double-blind, Phase 2 trial. Abstract LBA 74. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA SO 05 Diabetes in pregnancy, childhood and beyond]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66738.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Ribupatide phase 2 (obesity + PMOS). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.